Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…Abstract Number: 0060 • ACR Convergence 2024
Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA
Background/Purpose: Previous studies of RA patients have shown changes in NK cell populations (as defined by CD56 expression). The nature of these cellular changes remains…Abstract Number: 0952 • ACR Convergence 2024
Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Background/Purpose: Scleroderma-associated interstitial lung disease (SSc-ILD) is the leading cause of death among SSc patients. Loss of alveolar epithelial cells (AEC) and bronchial cell hyperplasia,…Abstract Number: 0954 • ACR Convergence 2024
Increased Proliferating Natural Killer Cells Exhibit an Aberrant Pro-Inflammatory Gene Signature in Systemic Sclerosis Patients
Background/Purpose: Recent transcriptomic data suggest a prominent involvement of innate immune cells in the pathogenesis of SSc. In this regard, contrasting data on NK cells…Abstract Number: 1702 • ACR Convergence 2024
Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors,…Abstract Number: 1705 • ACR Convergence 2024
Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a severe auto-inflammatory disorder associated with acquired mutations in the UBA1 gene that occur in hematopoietic stem cells…Abstract Number: 1763 • ACR Convergence 2024
Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset systemic lupus erythematosus (cSLE) are pediatric autoimmune diseases that can present with overlapping clinical features yet have unique tropism…Abstract Number: 1782 • ACR Convergence 2024
DOCK2 Mutations and Hyper-Inflammatory Syndromes
Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal hyper-inflammatory complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous…Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…Abstract Number: 2422 • ACR Convergence 2024
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Background/Purpose: Unprecedented clinical data have recently shown that patients with certain highly refractory autoimmune diseases (AI Dz) treated with conditioning chemotherapy (CCT) and autologous anti-CD19…Abstract Number: 0059 • ACR Convergence 2023
GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice
Background/Purpose: Human immunodeficiency virus (HIV) remains a significant life-threatening agent and burden on public health. Lesser studied and understood aspects of HIV include HIV-associated inflammatory…Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…Abstract Number: 0163 • ACR Convergence 2022
Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic
Background/Purpose: Prior research has shown that viruses may trigger JDM, although the degree to which COVID-19 may serve as a trigger for JDM remains unknown.…Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…